Replies to post #208881 on NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Regarding issues with published research, which is related to Xena and LF reply in the related thread:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146194974


The Ioannidis article I linked to (“Why Most Published Research is Wrong) is of interest to be sure, but it’s heavy reliance on statistics make its potential audience significantly less than I intended. It’s theoretical nature also presents issues of interpretation and application that make it less valuable, in the sense of raising more questions than it answers.

The article I actually meant to reference was the following that discusses Amgen’s attempt to reproduce “landmark” preclinical research in oncology:

Fifty-three papers were deemed 'landmark' studies. It was acknowledged from the outset that some of the data might not hold up, because papers were deliberately selected that described something completely new, such as fresh approaches to targeting cancers or alternative clinical uses for existing therapeutics. Nevertheless, scientific findings were confirmed in only 6 (11%) cases. Even knowing the limitations of preclinical research, this was a shocking result.

https://www.nature.com/articles/483531a#t1

The mix up was due to late night faulty memory of articles I read 10 years ago.